Medpace Holdings, Inc. (MEDP) Financial Statements
Industry: Commercial Physical & Biological Research (Services)
In fiscal 2025, Medpace reported revenue of $2.53B, up 20.0% from $2.11B the year before. Net income was $451.1M (a 17.8% net margin), or $15.28 per diluted share. Gross margin was 21.1% and operating margin was 21.1%. Operating activities generated $713.2M of cash, leaving $681.9M of free cash flow. At fiscal year end, Medpace held $1.98B in total assets against $1.52B in total liabilities, including $497.0M of cash and equivalents.
Open the full interactive Medpace financials → Quarterly statements, key ratios, valuation history and price charts.
Medpace Key Stats
| Share Price | $609.89 |
|---|---|
| Market Cap | $17.41B |
| P/E Ratio | 39.9 |
| Revenue YoY Growth | +20.0% |
| 52-Week Range | $393.42 – $630.19 |
| Shares Outstanding | 28.2 million (basic, 2026 Q2) |
Medpace Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $925.9M | $1.14B | $1.46B | $1.89B | $2.11B | $2.53B |
| Cost of Goods Sold | $758.9M | $943.8M | $1.18B | $1.55B | $1.66B | $2.00B |
| Gross Profit | $167.0M | $198.6M | $278.7M | $336.8M | $446.9M | $534.9M |
| Operating Income | $167.0M | $198.6M | $278.7M | $336.8M | $446.9M | $534.9M |
| Pre-Tax Income | $168.5M | $201.9M | $282.9M | $335.7M | $475.9M | $542.4M |
| Income Tax | $23.1M | $20.0M | $37.5M | $52.9M | $71.5M | $91.3M |
| Net Income | $145.4M | $181.8M | $245.4M | $282.8M | $404.4M | $451.1M |
| Diluted EPS | $3.84 | $4.81 | $7.28 | $8.88 | $12.63 | $15.28 |
Medpace Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $659.9M | $708.5M | $706.6M | $707.3M |
| Net Income | $111.1M | $135.1M | $123.9M | $121.4M |
| Diluted EPS | $3.86 | $4.58 | $4.28 | $4.25 |
Medpace Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $277.8M | $461.3M | $28.3M | $245.4M | $669.4M | $497.0M |
| Current Assets | $473.7M | $690.9M | $334.0M | $593.8M | $1.03B | $989.6M |
| Total Assets | $1.39B | $1.66B | $1.35B | $1.66B | $2.10B | $1.98B |
| Current Liabilities | $440.1M | $557.2M | $803.5M | $925.1M | $1.10B | $1.34B |
| Total Long-Term Debt | — | — | $50.0M | — | — | — |
| Total Liabilities | $584.9M | $707.0M | $966.1M | $1.10B | $1.28B | $1.52B |
| Shareholders' Equity | $805.8M | $952.9M | $386.4M | $559.0M | $825.5M | $459.1M |
Medpace Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $258.7M | $263.3M | $388.1M | $433.4M | $608.8M | $713.2M |
| Cash From Investing | -$31.2M | -$31.4M | -$38.7M | -$34.6M | -$28.3M | -$31.1M |
| Cash From Financing | -$82.3M | -$44.5M | -$775.8M | -$182.6M | -$154.0M | -$860.4M |
| Free Cash Flow | $227.3M | $235.1M | $351.2M | $396.7M | $572.3M | $681.9M |
Figures from Medpace's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Medpace financials page for every line item.
Medpace Company Profile
| Ticker | MEDP |
|---|---|
| Exchange | Nasdaq |
| Industry | Commercial Physical & Biological Research (Services) |
| Headquarters | Cincinnati, Ohio |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001668397 |
Frequently Asked Questions
What was Medpace's revenue in fiscal 2025?
Medpace (MEDP) reported revenue of $2.53B for fiscal 2025.
What is Medpace's annual revenue history?
Medpace's annual revenue by fiscal year: 2020: $925.9M; 2021: $1.14B; 2022: $1.46B; 2023: $1.89B; 2024: $2.11B; 2025: $2.53B.
What was Medpace's net income in fiscal 2025?
Medpace reported net income of $451.1M for fiscal 2025.
What was Medpace's earnings per share (EPS) in fiscal 2025?
Medpace's diluted EPS was $15.28 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Medpace generate in fiscal 2025?
Medpace generated $681.9M of free cash flow in fiscal 2025.
What was Medpace's revenue last quarter?
In its most recent reported quarter (2026 Q2), Medpace reported revenue of $707.3M.
How many shares of Medpace are outstanding?
Medpace reported a weighted average of 28.2 million basic shares outstanding in 2026 Q2.
What is Medpace's market cap?
Based on its latest closing price, Medpace (MEDP) has a market capitalization of about $17.41B.
When does Medpace's fiscal year end?
Medpace's fiscal year end, as registered with the SEC, is December 31.
Where is Medpace headquartered?
Medpace lists its business address in Cincinnati, Ohio in its SEC filings.